Ovarian cancer - topotecan (replaced by TA91)
Summary
This guidance is replaced by TA91 Ovarian cancer (advanced) - paclitaxel, pegylated liposomal doxorubicin hydrochloride and topotecan (review).
Guidance documents
Implementing this guidance
Other information
About this guidance
Technology appraisals TA28
Issued: July 2001
How this guidance was produced